3rd Annual Oligonucleotides for CNS Summit

With approvals in siRNA technology, more ASOs hurtling towards human trials in neurology, and exciting headlines in Alzheimer's and ALS, the draw of CNS targets for oligonucleotides has never been greater. Massive investments and growing pipelines in pharma and biotech alike are working to make these life-changing therapies a reality for previously undruggable targets.

Join 100+ experts and dedicated scientists at the 3rd Oligonucleotides for CNS, the definitive industry forum bringing together leaders to problem-solve, explore invention, and inspire the creation of next-generation oligonucleotide drugs for neurological disorders. Gather with specialists from Biogen, Ionis, Genentech, Eli Lilly, Servier, and Stoke, spanning disciplines of biology, chemistry, toxicology, and clinical innovation.

Tackle genomic target validation, backbone chemistry, effective intracellular delivery, and potency, increased stability for reduced dosing, novel cerebral organoids, CNS device delivery, and CSF oligo distribution to uncover the best approaches for each phase in your pipeline. Take away invaluable lessons that will translate directly into optimizing your oligonucleotide pipeline for the CNS.

URLs:
Website: https://go.evvnt.com/1546537-0?pid=10018
Tickets: https://go.evvnt.com/1546537-2?pid=10018
Brochure: https://go.evvnt.com/1546537-3?pid=10018

Prices:
Drug Developer - 2 Day Conference + 2 Workshops: USD 3597.00,
Drug Developer - 2 Day Conference + 1 Workshop: USD 3098.00,
Drug Developer - 2 Day Conference Only: USD 2599.00,
Solution Provider - 2 Day Conference + 2 Workshops: USD 5297.00,
Solution Provider - 2 Day Conference + 1 Workshop: USD 4548.00,
Solution Provider - 2 Day Conference Only: USD 3799.00

Speakers: Aaron Yarlas Director, Clinical Outcome Assessments, Ionis Pharmaceuticals, Aimee Jackson, Chief Scientific Officer, Atalanta Therapeutics, Anne Valat, principal scientist, Bolden Therapeutics, Apoorva Sarode, Principal Scientist, Genentech Inc, Benjamin Bleier, Associate Professor, Harvard Medical School, Dan Elbaum, Chief Scientific Officer, QurAlis Corp, Eric Green, Chief Scientific Officer, Maze Therapeutics, Graham Dempsey, Chief Scientific Officer and Senior Vice President - Research and Development, Q-State Biosciences, Helene Tran, Oligo Therapeutics Program Science Lead, Servier, Jessica Hurt, Director Genomic Targets, Biogen Idec, John Lewis, Founder and Chief Executive Officer, Entos Pharmaceuticals, Julia Alterman, Assistant Professor, University of Massachusetts Medical School, Mansoor Amiji, University Distinguished Professor, Northwestern University, Marjoke Debets, Director - Research and Development, Eli Lilly and Co., Mark DeAndrade, Associate Director, CNS Gene Therapy, Avrobio, Meena Meena, Senior Vice President - Drug Metabolism, Pharmacokinetics and Bioanalysis, Immunogenicity and Biomarkers, Stoke Therapeutics Inc., Michael Breen, Assistant Professor, Icahn School of Medicine at Mount Sinai, Miguel Rodriguez, de los Santos Postdoctoral researcher, Icahn School of Medicine at Mount Sinai, Nicole Datson, Chief Development Officer, Vico Therapeutics BV, Nikolaos Giagtzoglou, Principal Scientist, CAMP4 Therapeutics, Paul Peng Director, Oligonucleotide Technical Development, Biogen, Steven Petrou, Chief Scientific Officer, Praxis Precision Medicines, Inc., Sudhir Agrawal, President - Research, ARNAY Sciences, Thomas Gaj, Assistant Professor, University of Illinois, Wen-Hsuan Chang, Head of Target Validation, AcuraStem, William Drury, Director of Chemistry Innovation, Deep Genomics, Xiaobo Zhong, Professor, University of Connecticut, Zhen LI, CEO, ADARx Pharmaceuticals Inc.

Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States